The board of directors of HBM Holdings Limited announced that the National Medical Products Administration of China (the NMPA) has officially accepted the biologics license application for batoclimab (HBM9161) for treatment of generalized myasthenia gravis ("gMG"). On 6 March 2023, the Company announced positive topline results of its Phase III clinical trial of batoclimab (HBM9161) for the treatment of gMG. Result of the Phase III Trial met primary efficacy endpoint as well as key secondary endpoints with a favorable safety profile.

Batoclimab (HBM 9161) is a product to treat multiple pathogenic-IgG mediated autoimmune diseases with significant unmet medical needs. gMG is among the first of such multiple indications and this therapy received the "Breakthrough Therapy Certificate" from the NMPA in early 2021 and released the positive topline data of Phase II clinical trial in July 2021. In October 2022, the Company entered into a license agreement with NBP Pharma, a wholly owned subsidiary of the CSPC Group, to advance the development and commercialization of batoclimab in Greater China.